We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals
CRBP

100 hedge funds and large institutions have $108M invested in Corbus Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 25 increasing their positions, 23 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

16,967% more call options, than puts

Call options by funds: $512K | Put options by funds: $3K

211% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 9

23% more funds holding

Funds holding: 81 → 100 (+19)

3.64% more ownership

Funds ownership: 71.81% → 75.45% (+3.6%)

9% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 23

1% less capital invested

Capital invested by funds: $109M → $108M (-$1.53M)

Holders
100
Holders Change
+19
Holders Change %
+23.46%
% of All Funds
1.22%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
28
Increased
25
Reduced
23
Closed
9
Calls
$512K
Puts
$3K
Net Calls
+$509K
Net Calls Change
-$4.18M

Top Buyers

Rank Fund Capital Flow
1
Aberdeen Group
Aberdeen Group
United Kingdom
+$14M
2
Citadel Advisors
Citadel Advisors
Florida
+$10.4M
3
O
OrbiMed
New York
+$5.25M
4
SCM
Stonepine Capital Management
Oregon
+$4.81M
5
AC
Armistice Capital
New York
+$4.25M

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$1.97M
2
Morgan Stanley
Morgan Stanley
New York
-$1.63M
3
TCM
Tang Capital Management
California
-$1.61M
4
HS
HighVista Strategies
Massachusetts
-$1.49M
5
Millennium Management
Millennium Management
New York
-$1.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
JF
26
Jump Financial
Illinois
$491K +$744K +60,300 New
Acadian Asset Management
27
Acadian Asset Management
Massachusetts
$489K -$292K -23,630 -28%
SFCM
28
Seven Fleet Capital Management
California
$462K +$700K +56,750 New
CM
29
Caption Management
Oklahoma
$456K +$692K +56,066 New
State Street
30
State Street
Massachusetts
$448K – – –
UBS Group
31
UBS Group
Switzerland
$417K -$102K -8,287 -14%
Goldman Sachs
32
Goldman Sachs
New York
$386K +$174K +14,086 +42%
Northern Trust
33
Northern Trust
Illinois
$339K +$179K +14,463 +53%
BRF
34
B. Riley Financial
California
$315K +$478K +38,714 New
Millennium Management
35
Millennium Management
New York
$302K -$1.23M -99,364 -73%
OAC
36
OMERS Administration Corp
Ontario, Canada
$244K +$370K +30,000 New
QC
37
Quadrature Capital
United Kingdom
$243K +$369K +29,889 New
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$234K +$224K +18,167 +171%
Jane Street
39
Jane Street
New York
$228K -$371K -30,087 -52%
TI
40
Trexquant Investment
Connecticut
$222K +$186K +15,110 +124%
A
41
AlphaQuest
New York
$186K +$48.3K +3,912 +21%
Morgan Stanley
42
Morgan Stanley
New York
$182K -$1.63M -132,461 -86%
BHCM
43
Brevan Howard Capital Management
Jersey
$153K +$232K +18,795 New
PFCS
44
Pale Fire Capital SE
Czech Republic
$152K +$230K +18,650 New
LCM
45
Laurion Capital Management
New York
$151K +$230K +18,600 New
PCM
46
Prelude Capital Management
New York
$145K -$607K -49,203 -73%
EGM
47
Engineers Gate Manager
New York
$140K +$212K +17,143 New
Hudson Bay Capital Management
48
Hudson Bay Capital Management
Connecticut
$139K +$211K +17,089 New
Mariner
49
Mariner
Kansas
$139K -$46.3K -3,754 -18%
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$135K +$15.4K +1,247 +8%
1
2
3 4 5

CRBP Hedge Fund Activity: Q4 2025 in Review

100 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2025, worth a combined $108M — down 1.4% from $109M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new CRBP positions and 9 closed out — a net gain of 19 holders — while 25 added to existing stakes and 23 trimmed.

The largest buyer was Aberdeen Group, adding an estimated $14M. The largest seller was Octagon Capital Advisors, cutting an estimated $1.97M.

  • 100 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2025, up from 81 in Q3 2025.
  • Funds reported $108M of Corbus Pharmaceuticals stock for Q4 2025, down 1.4% quarter-over-quarter.
  • 28 funds opened new Corbus Pharmaceuticals positions in Q4 2025 and 9 closed out, a net change of +19 holders.
  • The largest Corbus Pharmaceuticals buyer in Q4 2025 was Aberdeen Group, an estimated $14M added.
  • The largest Corbus Pharmaceuticals seller in Q4 2025 was Octagon Capital Advisors, an estimated $1.97M sold.

Based on aggregated 13F filings for Q4 2025.